This study was motivated by previous findings that identified increasing circulating levels of fibroblastic growth factor 23 (FGF23), which regulates phosphate and bone metabolism, as a decisive independent risk factor for both CKD and CVD [118]; whilst the RAS is activated in CKD [119] and contributes to increased cardiovascular mortality and renal failure progression. The gene discussed is FGF23; the disease is chronic kidney disease.